Arbutus Biopharma
ABUS
ABUS
162 hedge funds and large institutions have $365M invested in Arbutus Biopharma in 2025 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 66 increasing their positions, 43 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
6% less capital invested
Capital invested by funds: $390M → $365M (-$24.9M)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
162
Holding in Top 10
3
Calls
$3.27M
Puts
$1.59M
Top Buyers
| 1 | +$3.09M | |
| 2 | +$3.02M | |
| 3 | +$2.98M | |
| 4 |
UBS AM
Chicago,
Illinois
|
+$2.96M |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.93M |
Top Sellers
| 1 | -$1.63M | |
| 2 | -$1.5M | |
| 3 | -$1.4M | |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$868K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$565K |
